Foghorn Therapeutics Inc. (FHTX)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Do Nothing: avgDollarVolume20 is $1.26M, below the $5.00M liquidity floor, so this breakout is not tradable under the strategy.
Company overview
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to address genetically determined vulnerabilities. Its pipeline includes FHD-286 for metastatic uveal melanoma and acute myeloid leukemia, and FHD-609 for synovial sarcoma.
Fundamental
fairStrong liquidity offsets ongoing losses, but profitability remains weak, resulting in a mixed fundamental score.
Mixed: strong liquidity runway (cash & marketable securities ~$168M; runway into 1H 2028 per Aug 2026 8-K) offsets ongoing losses and cash burn (TTM FCF yield ~-22%). Valuation is hard to anchor (no meaningful P/E; discounted-cash-flow outputs are negative), and risk remains high (beta ~2.84; Altman Z-score -3.89).
Sentiment
fairMedia coverage is mildly positive post-earnings, but retail interest and scheduled catalysts are lacking.
Last ~14d coverage skewed bullish as Foghorn’s Q2 results/corporate update (2026-08-06, announced) was framed as a revenue beat with pipeline progress, followed by mildly positive analyst/consensus recaps. Baseline (30–90d) coverage was too sparse to compute a reliable sentiment delta and Reddit chatter is absent; no investigations surfaced, but court-case discovery was partially blocked (CAPTCHA).
Technical
goodThe stock is in a strong short-term uptrend, but liquidity constraints limit tradability.
Price is above SMA20/50/200, EMA9/21, and the latest daily VWAP, while MACD is positive above signal and zero and ADX 41.80 confirms a strong post-catalyst trend; RSI 72.69 and Williams %R -9.73 show the move is extended, so the chart is strong but not perfect.
You’re looking at 2026-08-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.